RA Capital Management and Nextech Invest led a $105m Series B round in Boundless Bio, a next-generation precision oncology company, with participation from Fidelity Management & Research Company, Redmile Group, Wellington Management, Surveyor Capital, PFM Health Sciences, Logos Capital, ARCH Venture Partners, City Hill Ventures, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital and Alexandria Venture Investments. "RA Capital has been following the Boundless Bio story for some time now and believes that the team has developed industry-leading expertise in the biology that underlies high unmet need, gene amplified tumors," Zach Scheiner, RA Capital Management Principal.